Clinical Pearls for Carboplatin in HIPEC
Carboplatin is NOT the recommended agent for HIPEC in ovarian cancer—cisplatin at 75-100 mg/m² is the guideline-endorsed choice based on survival benefit data. 1, 2
Agent Selection and Dosing
Cisplatin remains the standard HIPEC agent with the most robust evidence, specifically at 100 mg/m² as used in the pivotal M06OVH-OVHIPEC trial that demonstrated improved disease-free survival (HR 0.63) and overall survival (HR 0.70) 1, 2
If carboplatin is used for HIPEC (off-guideline), the dose of 800 mg/m² has been studied with acceptable pharmacokinetic profiles and hematological toxicity 3
Carboplatin demonstrates a 12-fold higher concentration in perfusate versus plasma (mean Cmax 348 µg/mL vs 29 µg/mL) with a terminal half-life of approximately 104 minutes in perfusate 3
Technical Parameters
Temperature: 41-43°C (most commonly 42-43°C) maintained throughout perfusion 1, 2
Duration: 60-90 minutes depending on agent and dose, with 90 minutes being standard for cisplatin protocols 1, 2
Both open and closed abdominal techniques are acceptable based on institutional expertise 2
Patient Selection Criteria
HIPEC is recommended ONLY after neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS), not after primary debulking surgery 2
Patients must have stage III-IV epithelial ovarian cancer with response or stable disease after 3 cycles of NACT (4-6 cycles allowed) 2
Complete cytoreduction (R0 resection) is the goal before HIPEC administration, as residual disease is the strongest predictor of overall survival 2
Patients should have normal renal function before starting, appropriate performance status, and no pre-existing conditions that could worsen significantly (e.g., pre-existing neuropathy) 4
Systemic Chemotherapy Integration
Standard NACT regimen: Carboplatin AUC 5-6 + paclitaxel 175 mg/m² administered systemically before surgery 1
Minimum 6 total cycles of chemotherapy required, including at least 3 cycles of adjuvant therapy after IDS with HIPEC 2
The optimal pairing of pre/postoperative systemic regimens with HIPEC agents has not been definitively determined 2
Toxicity Management
Hematological toxicity is dose-limiting for carboplatin, with grade 3 neutropenia occurring in approximately 13% at 800 mg/m² dose 3
Carboplatin demonstrates linear pharmacokinetics with clearance proportional to glomerular filtration rate (GFR), making renal function critical for dosing 5
Large interindividual pharmacokinetic variability exists, making systemic exposure difficult to predict even with standardized dosing 3
When cisplatin is used (preferred agent), renal toxicity is a major concern—intravenous hydration before and after HIPEC (5-7 days) is essential to prevent nephrotoxicity 4
Procedural Considerations
Median procedure time: 300-600 minutes for combined cytoreductive surgery plus HIPEC 2
Median hospital stay: 8-24 days with significant blood loss common (>50% requiring transfusions in some series) 2
Major/severe complications occur in 9-40% of patients within 30 days, including fistulas, abscesses, infections, bowel perforation, ileus, hemorrhages, venous thromboembolism, and renal failure 2
Intraoperative and postoperative mortality ranges from 0-7%, though most recent trials report no procedure-related deaths 2
Critical Pitfalls to Avoid
Do not use HIPEC after primary debulking surgery—initial randomized trial data showed no benefit in this setting 2
Do not proceed with HIPEC if complete cytoreduction cannot be achieved—suboptimal debulking negates potential HIPEC benefits 2
Monitor renal function closely post-procedure—creatinine clearance can be reduced to <30 mL/min in patients receiving cisplatin at higher doses (80 mg/m²), with 70 mg/m² being the recommended maximum 6
Carboplatin dosing based solely on body surface area is inadequate—use the Calvert formula incorporating GFR: dose (mg) = AUC × [GFR + 25] for systemic administration 7